Ophthalmic Device Market Analysis, Size, Trends | Europe | 2017-2023 | MedSuite

  • Year: 2017
  • Scope: 2013-2023
  • Region: Europe
  • Pages: 630
  • Published Date: 8/1/2016
  • Type: MedSuite

The fastest growing segment in 2016 was the phacoemulsification console market. The phacoemulsification console market is expected to grow over the forecast period because of demand placed by the increasing prevalence of cataracts. Moreover, the ASP of these machines will slightly rise due to the incorporation of technological innovations. Additionally, because of the evolving technology, the lifespan of a phacoemulsification console is only approximately five years.

In 2016, the second fastest growing segment of the European ophthalmic device market was the segment for perimeters. A large number of devices in the install base are approaching obsolescence, driving a period of high sales for this market. Perimeters are used to analyze the visual field as part of the diagnosis of glaucoma. Because of the aging European population and the prevalence of glaucoma in old age, there will remain a strong demand for perimeters even after most of the obsolete units have been replaced. This growth is expected to accelerate slightly over the forecast period. Perimeters represent a relatively small amount of the overall ophthalmic device market. The market for slit lamps declined slightly in 2016. One of the reasons for the slow growth is the influx of competitors from Chinese manufacturers. This is especially the case for high-mount slit lamps which had traditionally been dominated by Heidelberg Engineering who is noted as a premium device manufacturer.  Not only does the competition dilute the market, but new competitors often undercut prices, leaving the established companies with no choice but to adjust their pricing in response.
To read more about the European ophthalmic device market trends, take a look at our latest Expert Article from our Analysts:

Overall, the European market for ophthalmic devices was valued at €1.831 billion in 2016. This is expected to increase over the forecast period at a CAGR of 1.3% to reach €2.014 billion.

While this report suite contains all ophthalmic device data, each of the markets are also available as stand alone MedCore reports. This allows you to get access to only the ophthalmic market research that you need. You can view these separate reports and segmentation here:


Of course, buying all of these reports together in this suite package will provide you with substantial discounts from the separate prices. Ask for a Quote to Learn More

Ophthalmic Device Market Report Data Types

  • Unit Sales, Average Selling Prices, Market Value & Growth Trends
  • Forecasts Until 2023, and Historical Data to 2013
  • Market Drivers & Limiters for Each Ophthalmic Device Segment
  • Competitive Analysis with Market Shares for Each Segment
  • Recent Mergers & Acquisitions
  • Disease Overviews and Demographic Information
  • Company Profiles for Top Competitors
  • Related Press Releases from Top Competitors

Ophthalmic Device Market Share Analysis

In 2016, Alcon was the leading competitor in the European ophthalmic device market. Alcon led the IOL and phacoemulsification console markets that year. Alcon manufactures the AcrySof® family of lenses. For patients with cataracts and preexisting presbyopia, Alcon manufactures the AcrySof®IQ ReSTOR® lens, which corrects for both conditions at the same time and offers patients the possibility of being much less dependent on glasses after cataract surgery. Alcon also carries the AcrySof®IQ Toric IOL, which corrects for astigmatism, and the AcrySof®IQ Aspheric IOL, which compensates for spherical aberration. Alcon’s strong position in the markets for surgical equipment gives the company an advantage when it comes to the sale of consumable products. Having equipment in the OR means that Alcon representatives maintain close relationships with surgeons. While representative are in the OR to perform upgrades and maintenance, they are able to assess their clients’ needs and recommend additional solutions. This generates an opportunity to discuss consumable products on a more frequent basis.

In 2016, Abbott Medical Optics (AMO) was the second leading competitor in the European ophthalmic device market. AMO was the market leader in the OVD market. They have a diverse portfolio of OVDs that include dispersive, cohesive and combination OVDs as a part of their HEALON® line of products. AMO’s OVD sales are strongly tied to the success of their IOL sales and thus, as expected, have strong OVD sales in the same countries in which they have a strong IOL presence. AMO’s IOLs have had particular success in the U.K. and German markets, where the company has strong relationships with ophthalmologists. In contrast, their positions in France and Spain were weaker. AMO is focused on innovation in the advanced technology lens segments. They are focused on driving innovation to doctors and increasingly reaching out to the end-users of the lens, the patients, to educate and drive innovation. In the past, AMO has been relatively stagnant in terms of market share. However, at present, the company is making some gains in the market for premium lenses. In addition, AMO has been responsible for a number of advances in phacoemulsification technology over the past two decades and continues to contribute to innovation in the field.

Carl Zeiss Meditec is the third leading player in the European ophthalmic device market. Carl Zeiss differs from the other leading competitors in the market in that the company is a significant player in both the diagnostic and interventional segments. They are very strong in the markets for diagnostic equipment. For example, the company was the leading competitor in the large market for OCT devices and was also the leader of the market for perimeters. They also lead a third market, optical biometers and were a major competitor in the markets for fundus cameras and slit lamps. In terms of interventional ophthalmic equipment, Carl Zeiss Meditec remains a relatively minor player. In 2016, Carl Zeiss Meditec held the fifth position in the European IOL market  fourth in the OVD market, and eighth in the ophthalmic laser markete. Despite not being interventional market leaders, the size of these markets contributes significantly to Carl Zeiss’s share of the overall market.

Bausch & Lomb is another competitor whose strong position in the ophthalmic device market is derived almost entirely from their products in the interventional arena. In 2016, Bausch & Lomb was the fourth leading competitor in the European ophthalmic device market. Bausch & Lomb was a strong competitor in the wavefront aberrometer, IOL, OVD and phacoemulsification console markets. Unlike Alcon and AMO, Bausch & Lomb manufactures hydrophilic lenses. The advantages of hydrophilic lenses are high water content, high biocompatibility, low internal and external reflections to reduce glare and the ability to pass through very small surgical incisions.

Topcon is an important company in the market for ophthalmic devices. Not only does Topcon directly control a large share of the various diagnostic device markets, but they are also involved in the interventional markets through a number of exclusive distribution and partnership agreements. For example, Topcon has an exclusive partnership with Oculentis, the Dutch manufacturer of IOLs which covers the sales, marketing and product development aspects of Oculentis’ business in many European countries. Topcon is responsible for the sale of Oculentis’ IOLs, viscoelastics and retinal liquids in all Western European countries except for Germany. The agreement essentially allows Topcon to provide surgeons with both diagnostic and surgical solutions. Topcon also markets the LENSAR™ femtosecond laser system for cataract surgery.

FREE Sample Report

iData’s 9-Step Research Methodology

Our reports follow an in-depth 9-step methodology which focuses on the following research systems:

  • Original primary research that consists of the most up-to-date market data
  • Strong foundation of quantitative and qualitative research
  • Focused on the needs and strategic challenges of the industry participants

Step 1: Project Initiation & Team Selection During this preliminary investigation, all staff members involved in the industry discusses the topic in detail.

Step 2: Prepare Data Systems and Perform Secondary Research The first task of the research team is to prepare for the data collection process: Filing systems and relational databases are developed as needed.

Step 3: Preparation for Interviews & Questionnaire Design The core of all iData research reports is primary market research. Interviews with industry insiders represent the single most reliable way to obtain accurate, current data about market conditions, trends, threats and opportunities.

Step 4: Performing Primary Research At this stage, interviews are performed using contacts and information acquired in the secondary research phase.

Step 5: Research Analysis: Establishing Baseline Estimates Following the completion of the primary research phase, the collected information must be synthesized into an accurate view of the market status. The most important question is the current state of the market.

Step 6: Market Forecast and Analysis iData Research uses a proprietary method to combine statistical data and opinions of industry experts to forecast future market values.

Step 7: Identify Strategic Opportunities iData analysts identify in broad terms why some companies are gaining or losing share within a given market segment.

Step 8: Final Review and Market Release An integral part of the iData research methodology is a built-in philosophy of quality control and continuing improvement is integral to the iData philosophy.

Step 9: Customer Feedback and Market Monitoring iData philosophy of continuous improvement requires that reports and consulting projects be monitored after release for customer feedback and market accuracy.

Click Here to Read More About Our Methodology